Core Insights - Bicycle Therapeutics plc is under investigation for possible violations of federal securities laws, as announced by Levi & Korsinsky [1] - RBC Capital Markets downgraded Bicycle Therapeutics from Outperform to Sector Perform due to delays in the development of its drug, zelenectide pevedotin, which is intended for metastatic urothelial cancer [2] - Following the downgrade, Bicycle's American Depositary Receipt (ADR) price dropped over 7% on the same day [3] Company Developments - The delay in the drug's development is attributed to the decision to push dose selection to the first quarter of 2026, which raises concerns about increased competition in the urothelial cancer treatment market [2] - The competitive landscape is highlighted by the potential impact of a competing product from Pfizer, which may benefit from any further delays in Bicycle's drug development [2] Legal Context - Levi & Korsinsky LLP has a strong reputation in securities litigation, having secured significant settlements for shareholders and being recognized as one of the top firms in the United States for securities class actions [4]

Nov 18, 2025 2:54 PM Eastern Standard Time The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm Share LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights ...

Accessibility StatementSkip Navigation SAN FRANCISCO, Nov. 18, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The suits allege that aTyr and its top executives made false and misleading statements about the efficacy of its drug, Efzofitimod, leading investors to purchase stock at artificially inflated prices. At the heart ...

Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. by Berger Montague on behalf of investors who traded Cepton shares between July 29, 2024, and January 6, 2025, alleging misrepresentation and omission of material information regarding a merger proposal with Koito Manufacturing Co., Ltd. [1][3] Company Overview - Cepton, Inc. is a technology company based in San Jose, California, specializing in lidar solutions for automotive and smart infrastructure applications. The company was acquired by Koito in January 2025, and its stock is no longer publicly traded [2]. Allegations in the Lawsuit - The lawsuit claims that Cepton misrepresented and omitted critical information about a competing third-party bid that valued the company at more than double the price offered by Koito. The Board of Directors allegedly failed to evaluate or disclose this competing offer, which deprived shareholders of making informed decisions [3]. - Additionally, the lawsuit references documents indicating that Cepton's CEO had personal financial conflicts that improperly influenced the Board's decision to accept the Koito deal [4].

Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit due to alleged violations of securities laws, with claims that the company misrepresented its business prospects and financial performance during its IPO and subsequent reporting period [1][3][4]. Company Overview - Firefly Aerospace operates in the space and defense technology sector, providing mission solutions for national security, government, and commercial customers [2]. IPO Details - The company conducted its initial public offering on August 7, 2025, issuing approximately 19.3 million shares at an offering price of $45.00 per share [2]. Allegations of Misrepresentation - The lawsuit claims that Firefly Aerospace overstated demand and growth prospects for its Spacecraft Solutions offerings, as well as the operational readiness and commercial viability of its Alpha rocket program [3]. Financial Performance - In its first earnings report as a public company on September 22, 2025, Firefly Aerospace reported a loss of $80.3 million for Q2 2025, compared to a loss of $58.7 million in Q2 2024. Revenue was reported at $15.55 million, below analyst estimates of $17.25 million, and down 26.2% year-over-year [4]. - The Spacecraft Solutions business segment reported revenue of only $9.2 million, representing a 49% year-over-year decrease [4]. Stock Price Impact - Following the earnings report, Firefly Aerospace's stock price fell more than 15%. Additionally, on September 29, 2025, the company disclosed an issue with its Alpha Flight 7 rocket, leading to a further decline of over 20% in its stock price [4][5].

Nov 18, 2025 12:15 PM Eastern Standard Time Law Offices of Frank R. Cruz Encourages Freeport- McMoran Inc. (FCX) Shareholders to Inquire About Securities Fraud Class Action Share LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Freeport-McMoran Inc. ("Freeport†or the "Company†) (NYSE: FCX) securities between February 15, 2022 and September 24, 2025, inclusive (the "Class Period†). Freeport investor ...

Core Viewpoint - A class action lawsuit has been filed against Primo Brands Corporation (PRMB) for securities fraud, affecting shareholders who purchased stock during specified periods [1][5]. Summary by Sections Class Action Details - The lawsuit is on behalf of shareholders who acquired Primo Brands or Primo Water Corporation common stock between June 17, 2024, and November 8, 2024, and between November 11, 2024, and November 6, 2025 [1]. - Investors have until January 12, 2026, to file a lead plaintiff motion [1]. Company Events - On November 8, 2024, Primo Water merged with BlueTriton Brands, leading to the formation of Primo Brands [3]. - On August 7, 2025, the company reported disruptions in product supply and service due to rapid facility closures and headcount reductions, resulting in a stock price drop of $2.41, or 9.1%, closing at $24.00 per share [3]. - On November 6, 2025, the company announced a CEO replacement and lowered its full-year 2025 net sales and adjusted EBITDA guidance, causing a further stock price decline of $8.20, or 36.2%, to close at $14.46 per share [4]. Allegations in the Lawsuit - The lawsuit alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects [5][6]. - Specific failures included not disclosing poor merger integration tracking, major supply disruptions, and misleading positive statements regarding the company's business [6].

Core Viewpoint - Senate Democrats are investigating Fiserv, Inc. and its former CEO Frank Bisignano regarding potential mismanagement and misleading financial forecasts that led to significant investor losses [2][7]. Group 1: Financial Performance and Forecasts - Fiserv's stock price dropped 47% on October 29, 2025, following the release of Q3 2025 financial results, which were described as "abysmal" by analysts [2][5]. - The company revised its organic revenue growth expectations down to 3.5%-4% from a previously higher forecast, and adjusted its EPS outlook to $8.50-$8.60 [5][6]. - Fiserv's new CEO, Michael Lyons, indicated that previous growth assumptions were overly optimistic and difficult to achieve, leading to a reassessment of the company's financial guidance [6][7]. Group 2: Legal Actions and Investigations - A securities fraud class action lawsuit has been filed against Fiserv, representing investors who acquired securities between July 23, 2025, and October 29, 2025 [3][4]. - The investigation focuses on whether Fiserv misled investors regarding its business and growth prospects, particularly in light of the drastic share price decline [7][8]. - Hagens Berman is actively seeking information from investors who suffered losses and is investigating the claims related to Fiserv's financial disclosures [2][9].

Share SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, both dates inclusive (the "Class Period†), have until January 12, 2026 to seek appointment as lead plaintiff of the Freeport-McMoRan class action lawsuit. Captioned Reed v. Freeport-McMoRan Inc., No. 25-cv-04243 (D. Ariz.), the Freeport-McMoRan class action lawsuit charges ...

Core Viewpoint - Stride Inc. is facing a securities class action lawsuit from shareholders due to allegations of misleading investors with inflated metrics and operational flaws, resulting in a significant decline in stock price [1][4]. Company Overview - Stride Inc. is one of the largest providers of online educational services in the United States [1]. - The company has been accused of inflating student enrollment figures by including "ghost students" and misrepresenting its business model's strength [4][7]. Legal Proceedings - Prominent shareholder rights law firm Hagens Berman is investigating claims against Stride and its executives, urging affected investors to report their losses [2][7]. - The class period for the lawsuit is from October 22, 2024, to October 28, 2025, with a lead plaintiff deadline set for January 12, 2026 [3]. Allegations and Operational Issues - The lawsuit claims that Stride's assurances about strong business performance were false, particularly regarding its ability to recover from enrollment losses after Gallup-McKinley canceled its contract [3][4]. - Allegations include: - Inflated enrollment numbers by retaining "ghost" students [7]. - Increased student-to-teacher ratios and insufficiently licensed teachers [4][7]. - Ignoring compliance requirements and suppressing whistleblowers [7]. Financial Impact - Stride reported that "poor customer experience" led to an estimated loss of 10,000 to 15,000 enrollments [5]. - The company's guidance for 2026 indicates a sales growth forecast of only 5%, a significant decrease from the previous five years' annualized growth of 19% [6].